Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03980457

Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke

The goal of this study is to determine the efficacy of electromechanical exoskeleton-assisted gait training on rehabilitation functional outcomes in patients with stroke undergoing therapy in an in-patient rehabilitation facility.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Oklahoma City VA Health Care System

Oklahoma City, Oklahoma, 73104, United States

Location status: Recruiting

Location contact

Meheroz Rabadi, MD, MRCPI

CONTACT

[email protected]

405-456-5298

Meheroz Rabadi, MD, MRCPI

PRINCIPAL_INVESTIGATOR

About this study

Abstract

Objective: The goal of this study is to determine the efficacy of electromechanical exoskeleton-assisted gait training on rehabilitation functional outcomes in patients with stroke undergoing therapy in an in-patient rehabilitation facility.

Background:

Method: The investigators will study 50 patients with stroke consecutively admitted to a designated stroke rehabilitation unit in the Oklahoma City VA Medical Center. All patients will receive their daily 3-hours conventional therapy, plus an hour of either exoskeleton or over-ground gait training 3 times per week for 60 minutes. Patients were assigned to either the experimental (exoskeleton) or the control (over-ground) groups by computer-generated randomization. This is an open-label pragmatic trial, where neither the patients nor the clinicians could be masked to the intervention. Institution review board (IRB) approval will be obtained for the protocol. The demographic data to be collected includes: age, gender, race/ethnicity, stroke onset to admission, stroke types (ischemic/hemorrhagic), and stroke severity (on the National Institute of Health Stroke Severity [NIHSS] scale. Admission and discharge total Functional Independence Measure (FIM), spasticity and depression scores, ambulation velocity over 2-minutes (2-MWT) in feet/minute, and discharge disposition. The intervention is Indego® exoskeleton. The primary outcome measures were: changes in the FIM, depression and spasticity scores. The secondary outcome measure was discharge disposition. Continuous variables were analyzed using Students t-test, ordinal variables were analyzed using Mann-Whitney, and the nominal variables were analyzed using Chi-square analyses.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients with acute hemorrhagic or ischemic stroke documented clinically and by neuroimaging.
  • Medically stable from a cardio-respiratory stand point so that they can participate in daily therapies.
  • Depressed patients will be included in the study
  • Patients able to stand alone
  • Patients able to provide a written informed consent, from cognitively intact patients (admission Mini Mental Scale Examination [MMSE] greater than or equal to 21).

Exclusion criteria

  • Aphasic patients unable to communicate
  • Confused patients
  • Patients medically unstable
  • Patients unable to stand alone
  • Refusal to provide written informed consent

Treatment and study plan

Indego Exoskeleton

Device

Powered generated orthosis

Standard Rehabilitation

Other

Standard Rehabilitation

Primary outcomes

  1. The Functional Independence Measure (FIM™)

    Time frame: Baseline (Day 1) and at 4-weeks to measure change

    It measure the degree of disability as well as the progress patients make throughout their medical rehabilitation programs. FIM Scale score varies from minimum of 18 to maximum of 126. Higher score better the outcome.

  2. The two minute walk test (2-MWT)

    Time frame: Baseline (Day 1) and at 4-weeks to measure change

    It assess the walking distance over two minutes while moving at a comfortable speed. using any ambulation aids (such as cane, walkers, and rollators) used in everyday life. Normal walking speed is 360 ft.

Secondary outcomes

  1. Modified Ashworth Scale (MAS)

    Time frame: Baseline (Day 1) and at 4-weeks to measure change

    Clinical measure of degree of spasticity. Score varies from 0=normal tome to 4=part rigid in flexion and extension. Lower the score the better the outcome.

  2. Discharge disposition

    Time frame: 4-weeks

    Looks at effectiveness of rehabilitation as to how many patients are discharged home. Higher percentage 65% and above the better outcome.

  3. The Beck Depression Inventory (BDI)

    Time frame: Baseline (Day 1) and at 4-weeks to measure change

    It is a 21 item self-report rating inventory measuring characteristic attitudes and symptoms of depression. It ranges in value from 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows: 0-9 indicates person is not depressed, 10-18 indicates mild-moderate depression, 19-29 indicates moderate-severe depression and 30-63 indicates severe depression.

Study contacts

Contact information is provided by the study sponsor or research team.

Meheroz H Rabadi, MD, MRCPI

CONTACT

[email protected]

405-456-5298

Sponsors and collaborators

Lead sponsor

University of Oklahoma

Other

Registry information

Important dates

Study start
2021
Primary completion
2026
Study completion
2028
First posted
Jun 10, 2019
Registry last updated
Apr 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.